Orexo Q3 net loss more than triples year over year to SEK 96.4 million

Bitget2026/10/22 05:12

By:Bitget

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Orexo’s Q3 2026 net loss from continuing operations widened 18% year-on-year to SEK 117.9 million.
Net revenues dropped 83% year-on-year to SEK 800,000 due to lower Abstral and Edluar royalties.
The board resolved on an approximately SEK 250 million rights issue, subject to shareholder approval on November 6, 2026.
Izipry’s application was resubmitted to the FDA, with potential approval expected in the first half of 2027.
OX640’s first pivotal trial remains scheduled to begin in Q4 2026, with results expected in Q1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orexo AB published the original content used to generate this news brief on October 22, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Orexo Q3 net loss more than triples year over year to SEK 96.4 million

You may also like

Crypto prices